0001801385-23-000004.txt : 20230523 0001801385-23-000004.hdr.sgml : 20230523 20230523162320 ACCESSION NUMBER: 0001801385-23-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230519 FILED AS OF DATE: 20230523 DATE AS OF CHANGE: 20230523 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Romano Kathryn CENTRAL INDEX KEY: 0001801385 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38210 FILM NUMBER: 23949174 MAIL ADDRESS: STREET 1: C/O KRYSTAL BIOTECH, INC. STREET 2: 2100 WHARTON STREET, SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Krystal Biotech, Inc. CENTRAL INDEX KEY: 0001711279 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 821080209 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 BUSINESS PHONE: (412) 586-5830 MAIL ADDRESS: STREET 1: 2100 WHARTON STREET STREET 2: SUITE 701 CITY: PITTSBURGH STATE: PA ZIP: 15203 4 1 wf-form4_168487338437565.xml FORM 4 X0407 4 2023-05-19 0 0001711279 Krystal Biotech, Inc. KRYS 0001801385 Romano Kathryn C/O KRYSTAL BIOTECH, INC. 2100 WHARTON STREET, SUITE 701 PITTSBURGH PA 15203 0 1 0 0 Chief Accounting Officer 1 Common Stock 2023-05-19 4 M 0 12500 52.26 A 28484 D Common Stock 2023-05-19 4 S 0 12500 95.05 D 15984 D Common Stock 2023-05-19 4 M 0 12500 52.26 A 28484 D Common Stock 2023-05-19 4 S 0 12500 95.0449 D 15984 D Common Stock 2023-05-19 4 S 0 3428 95.0808 D 12556 D Common Stock 2023-05-22 4 M 0 2521 52.26 A 15077 D Common Stock 2023-05-22 4 S 0 2521 105.8036 D 12556 D Common Stock 2023-05-22 4 M 0 2570 52.26 A 15126 D Common Stock 2023-05-22 4 S 0 2570 106.8087 D 12556 D Common Stock 2023-05-22 4 M 0 1300 52.26 A 13856 D Common Stock 2023-05-22 4 S 0 1300 107.8777 D 12556 D Common Stock 2023-05-22 4 M 0 2955 52.26 A 15511 D Common Stock 2023-05-22 4 S 0 2955 109.1719 D 12556 D Common Stock 2023-05-22 4 M 0 3154 52.26 A 15710 D Common Stock 2023-05-22 4 S 0 3154 109.9933 D 12556 D Common Stock 2023-05-22 4 M 0 12500 63.55 A 25056 D Common Stock 2023-05-22 4 S 0 12500 110 D 12556 D Stock Option (Right to Buy) 52.26 2023-05-19 2023-05-19 4 M 0 12500 0 D 2030-01-30 Common Stock 12500.0 37500 D Stock Option (Right to Buy) 52.26 2023-05-19 2023-05-19 4 M 0 12500 0 D 2030-01-30 Common Stock 12500.0 25000 D Stock Option (Right to Buy) 52.26 2023-05-22 2023-05-22 4 M 0 12500 0 D 2030-01-30 Common Stock 12500.0 12500 D Stock Option (Right to Buy) 63.55 2023-05-22 2023-05-22 4 M 0 12500 0 D 2032-02-27 Common Stock 12500.0 37500 D The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $95.00 per share. The transaction was executed in multiple trades ranging from $95.0000 to $95.3800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates sales of 3,428 shares with a limit price of $95.00 per share. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $105.00 per share. The transaction was executed in multiple trades ranging from $105.3400 to $106.3100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $106.3700 to $107.0300. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $107.6900 to $108.4200. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $108.9000 to $109.5500. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The transaction was executed in multiple trades ranging from $109.9700 to $110.0000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. The Rule 10b5-1 trading plan started on January 16, 2023 and will terminate on January 16, 2024 and contemplates option exercises and sales of 12,500 shares with a limit price of $110.00 per share. The transaction was executed in a single trade. 50,000 options were granted that vest in four equal annual installments beginning on January 21, 2021. 50,000 options were granted that vest in four equal annual installments beginning on February 28, 2023. /s/ Kathryn Romano 2023-05-23